Retinal Biologics Market size is set to expand at a considerable pace from 2022 to 2028. This growth is mainly attributed to the growing prevalence of eye-related disorders like age-related macular degeneration across the globe. According to estimates from the WHO, almost 2.2 billion people suffer from near or distance vision impairment worldwide. This rising prevalence of vision impairment is in turn leading to a surge in demand for effective treatment solutions, such as retinal biologics. Retinal biologics refer to a novel medication category designed to target specific markers in the patient’s body to reduce the burden of various systemic or ocular diseases that may manifest in the eye.
One of the major factors powering market trends through 2028 is the escalating focus of enterprises worldwide on R&D efforts related to retinal therapeutics. Biologics firms are making targeted efforts to develop efficient treatment solutions for various eye-related disorders and are increasingly gaining approval from regulatory bodies like the U.S. FDA (United States Food and Drug Administration). For instance, in July 2021, Roche announced that its BLA (Biologics License Application) for faricimab was accepted by the U.S.FDA for the treatment of nAMD (neurovascular age-related macular degeneration) and DME (diabetic macular edema), which could contribute to the increasing usage of retinal biologics as the ideal treatment for ocular disorders worldwide.
Diabetic retinopathy (DR) is poised to emerge as a prominent indication segment for the market by 2028. The prevalence of DR has been growing exponentially across the globe, given the constant expansion of the diabetic population. According to IDF (International Diabetes Federation), more than 200 million new diabetes cases are expected to be registered worldwide by 2045. This will result in a significant rise in the risk of diabetic retinopathy, which is the most common cause of vision loss among diabetic patients. These factors could expedite the adoption of retinal biologics designed to address DR-related vision impairment.
Europe retinal biologics market is projected to depict a strong growth rate through 2028, on account of the rising cases of diabetes in countries like the UK. According to Diabetes UK, over 4.9 million people in the United Kingdom have diabetes, a number that is projected to increase to 5.5 million by 2030. This increasing diabetic population is a key contributing factor to the advancement of biologics for retinal treatment in the region. For instance, in September 2021, GenSight Biologics announced that its LUMEVOQ gene therapy received the designation of PIM (Promising Innovative Medicine) from the UK’s MHRA (Medicines and Healthcare products Regulatory Agency) for treating vision loss due to LHON (Leber Hereditary Optic Neuropathy).
Janssen Pharmaceuticals (Johnson & Johnson), OncoGene, Novartis AG, and Regeneron are some of the major entities operating in the global market. These players are involved in various strategies like partnerships and new product development to expand their presence across the global business landscape. For instance, in March 2021, SemaThera Inc. and Roche announced a multi-year research partnership and licensing agreement to advance SemaThera’s new biologics portfolio for the treatment of ischemic retinal diseases like diabetic retinopathy. In October 2021, the U.S. FDA announced its acceptance of Novartis’s sBLA (supplemental Biologics License Application) for Beovu® (brolucizumab) 6 mg for the treatment of DME (diabetic macular edema). The drug also received approval from the EMA (European Medicines Agency) for type-II variation application.
The coronavirus pandemic has created disruptions in care patterns across the globe and led to widespread changes in disease management across many therapeutic disciplines. Ophthalmology was initially one of the areas affected, with most healthcare facilities performing only urgent procedures. However, as more evidence regarding the COVID-19 emerges, the impact of the disease on eye health is becoming increasingly prevalent, leading to various studies and research efforts aimed at gaining a better understanding of the ocular manifestations of the infection. For instance, in February 2021, a new study conducted by the French Society of Neuroradiology found the occurrence of severe eye abnormalities like retinopathy among COVID-19 patients. Findings from this study have highlighted the significance of treatment and disease management protocols like regular eye screening and medication, which could amplify the demand for retinal biologics over the coming years.
Market, By Drug Class
Market, By Indication
Market, By Distribution Channel
The above information is provided for the following regions and countries: